CME/CE

Episodes 113-123 of 123

• 

  RestartResume

  Unmet needs in lowering LDL-c

  RestartResume

  Unmet needs in lowering LDL-c

  MinuteCE®

  Unmet needs in lowering LDL-c

  1.00 program credit

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  1.00 program credit

• 

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  RestartResume

  New insights on CETP inhibition from genetic research and clinical trials

  MinuteCE®

  New insights on CETP inhibition from genetic research and clinical trials

  1.00 program credit

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  1.00 program credit

• 

  MinuteCE®

  Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?

  1.00 credit 3 episodes

  • 

    

    Stephen Nicholls, FRACP, FACC, FESC, FAHA

  • 

    

    Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

  • 

    

    Roxana Mehran, MD

  1.00 credit 3 episodes

• 

  RestartResume

  Improving quality of life in patients with HCM

  RestartResume

  Improving quality of life in patients with HCM

  MinuteCE®

  Improving quality of life in patients with HCM

  1.00 program credit

  • 

    

    Carolyn Ho, MD

  1.00 program credit

• 

  MinuteCE®

  Seeing the forest through the trees  - Diagnosing and treating hypertrophic cardiomyopathy

  1.00 credit 3 episodes

  • 

    

    Antonis Pantazis, MD

  • 

    

    Pablo García-Pavía, MD, PhD

  • 

    

    Carolyn Ho, MD

  1.00 credit 3 episodes

• 

  RestartResume

  Hypertrophic cardiomyopathy: What are the concerns?

  RestartResume

  Hypertrophic cardiomyopathy: What are the concerns?

  MinuteCE®

  Hypertrophic cardiomyopathy: What are the concerns?

  1.00 program credit

  • 

    

    Antonis Pantazis, MD

  1.00 program credit

• 

  RestartResume

  Diagnostic challenges for symptomatic obstructive HCM

  RestartResume

  Diagnostic challenges for symptomatic obstructive HCM

  MinuteCE®

  Diagnostic challenges for symptomatic obstructive HCM

  1.00 program credit

  • 

    

    Pablo García-Pavía, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  New paradigms in the prevention of ASCVD: The role of EPA and triglycerides

  1.00 credit 3 episodes

  • 

    

    Richard Hobbs, MD

  • 

    

    Lale Tokgözoğlu, MD

  • 

    

    Victor Aboyans, MD, PhD

  1.00 credit 3 episodes

• 

  RestartResume

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  RestartResume

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  MinuteCE®

  The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

  1.00 program credit

  • 

    

    Lale Tokgözoğlu, MD

  1.00 program credit

• 

  RestartResume

  Reassessing the role of triglycerides in residual cardiovascular risk

  RestartResume

  Reassessing the role of triglycerides in residual cardiovascular risk

  MinuteCE®

  Reassessing the role of triglycerides in residual cardiovascular risk

  1.00 program credit

  • 

    

    Richard Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  RestartResume

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  MinuteCE®

  Integrating icosapent ethyl in preventive strategies: Practical guidance

  1.00 program credit

  • 

    

    Victor Aboyans, MD, PhD

  1.00 program credit